Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07938138
PHASE1

Safety and Tolerability of F012 in Patients With Hyperuricemia and Gout

Sponsor: The Affiliated Hospital of Qingdao University

View on ClinicalTrials.gov

Summary

This study is a randomized, double-blind, placebo-controlled single dose escalation (SAD) study conducted in patients with hyperuricemia with or without gout. The plan is to conduct ramp ups in 5 dose groups of 1mg, 2mg, 4mg, 6mg, and 8mg (adjustable during the study), with 8 subjects in each dose group and a total of 40 subjects. The sentinel method will be used for each dose group, with 2 subjects in the first group (1A+1P) followed by 6 subjects in the second group (5A+1P), to observe safety and tolerability.

Official title: A Randomized, Double-blind, Placebo-controlled, Single Dose Escalation Phase I Clinical Study Evaluating the Safety and Tolerability of F012 in Patients With Hyperuricemia and Gout

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2024-06-11

Completion Date

2025-11-30

Last Updated

2026-11-16

Healthy Volunteers

No

Interventions

DRUG

PEGylated uricase

Dilute F012 into 0.9% sodium chloride injection solution. Inject 1mg, 2mg, and 4mg dose groups intravenously with a syringe pump, and 6mg and 8mg dose groups intravenously for at least 2 hours.

DRUG

F012 placebo

Dilute placebo into 0.9% sodium chloride injection solution. Inject 1mg, 2mg, and 4mg dose groups intravenously with a syringe pump, and 6mg and 8mg dose groups intravenously for at least 2 hours.

Locations (1)

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, China